Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -70.80% is 60% below its 5-year average of -44.27%, around the middle of its 5-year range (-102.18%–-15.87%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.95% above its 12-month average of -78.62%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -70.80%.
RETURN ON INVESTED CAPITAL (ROIC)
-70.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-78.62%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-59.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-44.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+9.95%
CURRENT VS 3Y AVG
-19.99%
CURRENT VS 5Y AVG
-59.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.17%
median of 798 covered companies
CURRENT VS SECTOR MEDIAN
-101.30%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$214.17M
Return on Invested Capital (ROIC)
-70.80%
TTM Avg
-78.62%
3Y Avg
-59.00%
5Y Avg
-44.27%
Market Cap
$211.51M
Return on Invested Capital (ROIC)
-43.74%
TTM Avg
-105.81%
3Y Avg
-81.36%
5Y Avg
-65.49%
Market Cap
$213.84M
Return on Invested Capital (ROIC)
8.84%
TTM Avg
15.21%
3Y Avg
-9.34%
5Y Avg
-32.56%
Market Cap
$209.91M
Return on Invested Capital (ROIC)
26.14%
TTM Avg
3.79%
3Y Avg
-12.27%
5Y Avg
-17.37%
Market Cap
$218.14M
Return on Invested Capital (ROIC)
19.13%
TTM Avg
15.37%
3Y Avg
31.31%
5Y Avg
44.42%
Market Cap
$206.58M
Return on Invested Capital (ROIC)
-63.61%
TTM Avg
-17.34%
3Y Avg
-19.38%
5Y Avg
-26.83%
Market Cap
$206.11M
Return on Invested Capital (ROIC)
-33.10%
TTM Avg
-20.50%
3Y Avg
-16.94%
5Y Avg
-23.40%
Market Cap
$207.46M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.70M
Return on Invested Capital (ROIC)
-40.18%
TTM Avg
-34.28%
3Y Avg
-58.87%
5Y Avg
-58.87%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $214.17M | -70.80% | -78.62% | -59.00% | -44.27% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.51M | -43.74% | -105.81% | -81.36% | -65.49% |
| Niagen Bioscience Inc (NAGE)vs › | $213.84M | 8.84% | 15.21% | -9.34% | -32.56% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 26.14% | 3.79% | -12.27% | -17.37% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.14M | 19.13% | 15.37% | 31.31% | 44.42% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $206.58M | -63.61% | -17.34% | -19.38% | -26.83% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $206.11M | -33.10% | -20.50% | -16.94% | -23.40% |
| Electra Therapeutics Inc. (ETRA)vs › | $207.46M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $205.70M | -40.18% | -34.28% | -58.87% | -58.87% |
| Pro-Dex, Inc. (PDEX)vs › | $205.01M | 14.99% | 15.04% | 13.17% | 12.12% |
ROIC
-70.8%
ROE
-106.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -70.80% |
| 2026-03-31 | -61.17% |
| 2025-12-31 | -69.87% |
| 2025-09-30 | -89.10% |
| 2025-06-30 | -102.18% |
| 2025-03-31 | -92.80% |
| 2024-12-31 | -82.08% |
| 2024-09-30 | -37.12% |
| 2024-06-30 | -36.50% |
| 2024-03-31 | -36.54% |
| 2023-12-31 | -35.04% |
| 2023-09-30 | -27.23% |
| 2023-06-30 | -26.59% |
| 2023-03-31 | -21.68% |
| 2022-12-31 | -21.14% |
| 2022-09-30 | -24.05% |
| 2022-06-30 | -21.13% |
| 2022-03-31 | -22.39% |
| 2021-12-31 | -19.08% |
| 2021-09-30 | -17.32% |
| 2021-06-30 | -15.87% |
| 2021-03-31 | -27.41% |
| 2020-12-31 | -24.67% |
